To amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit, and for other purposes.
Summary
What This Bill Does
The bill creates restoration of amount of orphan drug tax credit Section 45C(a) of the Internal Revenue Code of 1986 is amended by striking 25 percent and inserting 50 percent and requires CDC feasibility study on surveillance infrastructure for rare diseases and conditions. It relies on compliance mandates, definition changes, tax credits, and reporting requirements. The main policy areas are Healthcare Consumers, Healthcare, and Science & Space.
Who Benefits and How
Public beneficiaries or protected communities affected by the clause could face reduced risk and Patients and health care consumers affected by the bill could gain revenue opportunities.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties, Researchers and scientific institutions affected by the bill would take on compliance duties, and Patients and health care consumers affected by the bill would take on compliance duties.
Key Provisions
- Creates restoration of amount of orphan drug tax credit Section 45C(a) of the Internal Revenue Code of 1986 is amended by striking 25 percent and inserting 50 percent.
- Requires CDC feasibility study on surveillance infrastructure for rare diseases and conditions.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates restoration of amount of orphan drug tax credit Section 45C(a) of the Internal Revenue Code of 1986 is amended by striking 25 percent and inserting 50 percent and requires CDC feasibility study on surveillance infrastructure for rare diseases and conditions.
Key Policy Areas
Healthcare Consumers, Healthcare, Science & Space
Primary Purpose
The bill creates restoration of amount of orphan drug tax credit Section 45C(a) of the Internal Revenue Code of 1986 is amended by striking 25 percent and inserting 50 percent and requires CDC feasibility study on surveillance infrastructure for rare diseases and conditions.
Policy Domains
Whole bill
Identified Gains
- Public beneficiaries or protected communities affected by the clause
- Patients and health care consumers affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Researchers and scientific institutions affected by the bill
- Patients and health care consumers affected by the bill
Sponsors
Josh Gottheimer
D-NJ | Primary Sponsor
Legislative Progress
IntroducedMr. Gottheimer (for himself and Mr. Bacon) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology